R&D channel feed

Flex sends out an SOS sig­nal, scrap­ping stud­ies and slash­ing staff as it hunts a sur­vival strat­e­gy — shares crater

7 years ago

Lit­tle vTv Ther­a­peu­tics adds an­oth­er round of bad da­ta on Alzheimer's drug, but they still love their chances

7 years ago

Galmed's stock rock­ets up as ex­ecs tout a mixed set of NASH da­ta

7 years ago

Roche CEO Sev­erin Schwan isn’t about to tam­per with a win­ning R&D strat­e­gy now, but he’s still look­ing for ways to cut costs

7 years ago

PhI­II Alzheimer’s drug goes bust — and a ma­jor set­back at Eli Lil­ly and As­traZeneca may doom the class

7 years ago

Sanofi builds on mR­NA al­liances with an $805M pact for Ron Re­naud’s Trans­late Bio

7 years ago
Pharma

Strike two: Vi­cal says an­oth­er one of its vac­cines has crashed and burned in PhII

7 years ago

Vi­su­al­ize: AS­CO 2018's win­ners and losers

7 years ago
Pharma

Af­ter snatch­ing up Shire's can­cer unit, French phar­ma gi­ant Servi­er to ex­pand US pres­ence with Kendall Square in­no­va­tion of­fice

7 years ago

Di­a­betes gi­ant No­vo said to con­sid­er up to 3,000 lay­offs as US pric­ing storms gath­er: re­port

7 years ago
Pharma

Re­lo­cat­ing its US HQ to Boston, French phar­ma Ipsen to add 250 jobs

7 years ago
Pharma

Gates Foun­da­tion sets up biotech-like in­sti­tute in hands-on ef­fort to spur drug de­vel­op­ment for ne­glect­ed dis­eases

7 years ago
Pharma

Bio­gen, Ei­sai BACE drug cuts amy­loid be­ta in the brain, but there’s no hard da­ta to show it does any­thing im­por­tant for cog­ni­tion

7 years ago

Pick­ing up the pieces left from an Alzheimer’s im­plo­sion, Ax­o­vant is start­ing over by div­ing in­to gene ther­a­py

7 years ago
Pharma

Gilead ups its bet on HIV, hep B, ink­ing $400M part­ner­ship with im­munother­a­py com­pa­ny Hookipa

7 years ago
Pharma

#AS­CO18: Ab­b­Vie con­vinces one top an­a­lyst that its $6B 'megablock­buster' Ro­va-T is worth­less

7 years ago

Vaxart re­ports PhII de­feat for a lega­cy an­tivi­ral from Avi­ra­gen — shares slide

7 years ago

#AS­CO18: Bris­tol-My­ers takes an­oth­er stab at a pos­i­tive im­pres­sion for Check­Mate-227

7 years ago

Nek­tar wants every­one to stay calm as they car­ry on with NK­TR-214, but #AS­CO18 spurs a stam­pede

7 years ago

Stan­ford spin­out Forty Sev­en ar­rives at AS­CO with a snap­shot of promis­ing CD47 da­ta — and a $115M IPO in hand

7 years ago
Financing

Roche dumps its PhI­II PI3K ef­fort on taselis­ib af­ter re­searchers track poor sur­vival edge, harsh side ef­fects for breast can­cer

7 years ago

Mer­ck­'s Keytru­da builds a com­mand­ing lead in front­line lung can­cer with da­ta from two more land­mark tri­als

7 years ago

Spurring move to per­son­al­ized ther­a­pies, Loxo el­bows its way back in­to the AS­CO spot­light with 2nd tis­sue-ag­nos­tic can­cer drug suc­cess

7 years ago
Pharma

Roche boasts of stalling lung can­cer with Tecen­triq/chemo com­bo -- but ri­val Mer­ck stays out front

7 years ago
First page Previous page 268269270271272273274 Next page Last page
A service from the Financial Times